Peer-Reviewed Publications - Shari Pilon-Thomas, Ph.D.


  1. Pilon-Thomas, S.A., Mackay, A., Vohra, N., and Mulé, J.J. Blockade of Programmed Death Ligand-1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.  J. Immunol. 184:3442-3449, 2010.  PMCID: PMC2913584
  2. Pilon-Thomas, S., Nelson, N., Vohra, N., Jerald, M., Pendleton, L., Szekeres,K, and Ghansah, T.  Murine pancreatic adenocarcinoma dampens SHIP-1 expression and alters MDSC homeostasis and function.  PLoS One, 6:e27729, 2011.  PMCID: PMC3222660
  1. Pilon-Thomas, S., Kuhn, L., Ellwanger, S., Janssen, W., Royster, E., Marzban, S., Kudchadkar, R., Zager, J., Gibney, G., Sondak, V.K., Weber, J., Mulé, J.J., Sarnaik, A.A. Brief Communication: Efficacy of Adoptive Cell Transfer of Tumor Infiltrating Lymphocytes after Lymphopenia Induction for Metastatic Melanoma. Journal of Immunotherapy 35:615-20, 2012. PMCID: PMC4467830
  2. Kodumudi, K., Weber, A., Sarnaik, A.A., Pilon-Thomas, S.  Blockade of myeloid derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma. Journal of Immunology 189(11): 5147-54, 2012. PMCID: PMC3505990
  3. Chacon, J.A., Wu, R.C., Sukhumalchandra, P., Molldrem, J.J., Sarnaik A, Pilon-Thomas, S., Weber, J., Hwu, P., Radvanyi, L. Co-Stimulation through 4-1BB/CD137 Improves the Expansion and Function of CD8(+) Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell Therapy. PLoS One, 8(4):e60031, 2013. Epub 2013 Apr 1. PMCID: PMC3613355
  4. Ghansah, T., Vohra, N., Kinney, K., Weber, A., Kodumudi, K., Springett, G., Sarnaik, A.A., Pilon-Thomas, S. Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma. Cancer Immunol Immunother., 62(6):1083-91, 2013. PMCID: PMC3666559
  5. Toomey, P., Kodumudi, K., Weber, A., Kuhn, L., Moore, E., Sarnaik, A.A., Pilon-Thomas, S. Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer. PLoS One. 8(7):e68561, 2013. PMCID: PMC3714270
  6. Chacon, J.A., Pilon-Thomas, S., Sarnaik, A.A., Radvanyi, L.G. Continuous 4-1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy. Oncoimmunology. 2(9):e25581, 2013. PMID: 24319633; PMCID: PMC3850170.
  7. Chacon, J., Sarnaik, A.A., Chen, J., Creasy, C., Kale, C., Robinson, J., Weber, J., Hwu, P., Pilon-Thomas, S.*, and Radvanyi, L. Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy.  Clinical Cancer Research, 21(3):611-21, 2015. PMCID: PMC4315752 *shared senior authorship
  8. Pilon-Thomas S, Kodumudi KN, El-Kenawi AE, Russell S, Weber AM, Luddy K, Damaghi M, Wojtkowiak JW, Mulé JJ, Ibrahim-Hashim A, Gillies RJ. Neutralization of tumor acidity improves antitumor responses to immunotherapy. Cancer Res. 76(6):1381-90, 2016. PMCID: PMC4829106
  9. Kodumudi KN, Siegel J, Weber AM, Scott E, Sarnaik AA, Pilon-Thomas S. Immune Checkpoint Blockade to Improve Tumor Infiltrating Lymphocytes for Adoptive Cell Therapy.  PLoS One.11(4):e0153053. 2016. PMCID:PMC4822778
  10. Liu H, Innamarato PP, Kodumudi K, Weber A, Nemoto S, Robinson JL, Crago G, McCardle T, Royster E, Sarnaik AA, Pilon-Thomas S.  Intralesional rose bengal in melanoma elicits tumor immunity via activation of dendritic cells by the release of high mobility group box 1. Oncotarget. 2016. PMCID: PMC5122358
  11. Hall, M., Liu, H., Malafa, M., Centeno, B., Pimiento, J., Hodel, P., Pilon-Thomas, S.*, Sarnaik, AA. Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors.  J Immunother Cancer. 4:61.2016. PMCID: PMC5067894. *shared senior authorship
  12. Mullinax, JE,  Hall, M.,  Prabhakaran, S.,  Weber, J,  Khushalani, N., Eroglu, Z, Brohl, A., Markowitz,J., Royster, E., Richards, A., Stark, V.,  Zager, JS.,  Kelley, L., Cox,C., Sondak, VK., Mule', JJ., Pilon-Thomas, S.*, and  Sarnaik, AA.  Combination Ipilimumab and Adoptive Cell Therapy with Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma.  Frontiers in Oncology. 2018. Front Oncol. 2018 Mar 2;8:44. PMCID: PMC5840208. *corresponding author and shared senior authorship
  13. Liu H, Weber A, Morse J, Kodumudi K, Scott E, Mullinax J, Sarnaik AA, Pilon-Thomas S.  T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1/PD-L1 pathway in a murine melanoma model. PLoS One. 2018 Apr 25;13(4):e0196033. PMCID: PMC5918896
  1. Poch M, Hall M, Joerger A, Kodumudi K, Beatty M, Innamarato PP, Bunch BL, Fishman MN, Zhang J, Sexton WJ, Pow-Sang JM, Gilbert SM, Spiess PE, Dhillon J, Kelley L, Mullinax J, Sarnaik AA, Pilon-Thomas S.  Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer.  Oncoimmunology. 2018 Jul 23;7(9):e1476816. PMCID: PMC6140546
  2. Hopewell EL, Cox C, Pilon-Thomas S, Kelley LL. Tumor-infiltrating lymphocytes: Streamlining a complex manufacturing process. Cytotherapy. 2018 Nov 30. pii: S1465-3249(18)30674-1. PMID: 30509772
  3. Atay C, Kwak T, Lavilla-Alonso S, Donthireddy L, Richards AD, Moberg VE, Pilon-Thomas S, Schell MJ, Messina JL, Rebecca VW, Xiao M, Tan J, Zhang G, Weber JS, Herlyn M, Sarnaik AA, Gabrilovich DI. BRAF targeting sensitizes resistant melanoma to cytotoxic T cells.  Clin Cancer Res. 2019 Feb 14. pii: clincanres.2725.2018. doi: 10.1158/1078-0432.CCR-18-2725. PMID: 30765391